Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer
Authors:
Open Access
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 4 (4) , 748-752
Abstract
No abstract availableKeywords
Funding Information
- Lung Cancer Research Foundation
This publication has 17 references indexed in Scilit:
- Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)European Urology, 2018
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancerOncotarget, 2017
- A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancersAnnals of Oncology, 2015
- Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma casesBritish Journal of Cancer, 2015
- Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Developing biomarker-specific end points in lung cancer clinical trialsNature Reviews Clinical Oncology, 2014
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageNature Medicine, 2014
- p53 at a glanceJournal of Cell Science, 2010
- Quantification of Free Circulating DNA As a Diagnostic Marker in Lung CancerJournal of Clinical Oncology, 2003